John A Lewicki

This inventor holds 52 USPTO granted patents and 8 published patent applications and 6 EPO patents, primarily in Cancer Treatment (CPC class C07K). Top assignees: Scios Inc., Oncomed Pharmaceuticals, Inc., California Biotechnology Inc.. Active years: 1984-2017.

USPTO Granted Patents = 52 (Patent Applications = 8)

% Patents Active = 75.0

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 3.8

ph-index = 22

Forward Citations = 1,370(Granted Patents)

Forward Citations (Not Self Cited) = 1,297(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Sunnyvale, CA (US) (1985 - 1993)
San Jose, CA (US) (1984 - 2007)
Los Gatos, CA (US) (1990 - 2017)

Company Filing History:

Oncomed Pharmaceuticals, Inc.

patents

5 out of 21

California Biotechnology Inc.

Biotechnology Research Associates, J.v.

Leland Stanford Junior University

patents

8. 1 out of 3,511

University of Michigan

patents

where one patent can have more than one assignee

Years Active: 1984-2017

Loading Chart...

Areas of Expertise:

Cancer Treatment

Monoclonal Antibodies

Notch Receptors

Wnt Signaling

Tumor Growth Inhibition

Diagnostic Methods

Polynucleotides

Biologically Active Polypeptides

Natriuretic Peptides

Cardiac Failure

Quinazoline Derivatives

Immunoassays

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9850311 - Compositions and methods for diagnosing and treating cancer (2017-12-26),

2. 9732139 - Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor (2017-08-15),

3. 9676865 - Antibodies to a non-ligand binding region of at least two NOTCH receptors (2017-06-13),

4. 9505832 - Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3 (2016-11-29),

5. 9228013 - Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell (2016-01-05),

6. 8980260 - Monoclonal antibody that binds human notch2 and notch3 (2015-03-17),

7. 8945873 - Polynucleotides encoding Notch receptor antibodies (2015-02-03),

8. 8784811 - Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1 (2014-07-22),

9. 8765913 - Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells (2014-07-01),

10. 8652472 - Compositions and methods for diagnosing and treating cancer (2014-02-18),

11. 8425903 - Methods of treatment by administering antibodies to notch receptors (2013-04-23),

12. 8404237 - Antibodies to the NOTCH1 receptor (2013-03-26),

13. 8324361 - Nucleic acid molecules encoding soluble frizzled (FZD) receptors (2012-12-04),

14. 8226943 - Antibodies to notch receptors (2012-07-24),

15. 8206713 - Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2 (2012-06-26),

Title: The Innovative Journey of John A Lewicki

Introduction: John A Lewicki, a visionary inventor based in San Jose, CA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: John A Lewicki holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his commitment to pushing the boundaries of innovation.

Career Highlights: With a career spanning over two decades, John A Lewicki has worked with leading tech companies in Silicon Valley, where he has played a key role in developing cutting-edge technologies that have revolutionized various industries.

Collaborations: Throughout his career, John A Lewicki has collaborated with top researchers, engineers, and scientists to bring his innovative ideas to life. His collaborative spirit has led to the successful implementation of groundbreaking technologies.

Conclusion: John A Lewicki's passion for innovation and his relentless pursuit of technological advancement have solidified his position as a prominent figure in the world of inventors. His contributions continue to inspire future generations of innovators to push the boundaries of what is possible.